M&A Leadership Council

SEPTEMBER 9, 2021

She has more than 16 years of C-level experience as a security and privacy consultant, strategist and systems implementer for large institutions in the financial services, insurance, health care and pharmaceuticals sectors. Prior to joining M&A Partners, Mr. Dickelman headed Innovation, Research & Development for U.S.

IT 52

IT M&A Insurance Securities 52

Cooley M&A

JANUARY 22, 2021

The second half of the year witnessed a rebound spurred by several multibillion-dollar deals, including Gilead’s acquisition of Immunomedics for nearly $21 billion and AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39 billion. While deal value was down for the year, deal volume was relatively stable (down only 2.0%

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years. time highs in 2021.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 22, 2025

While global M&A deal value across sectors remained relatively flat overall , pharmaceuticals and life sciences M&A in 2024 dipped relative to the prior year. Indeed, the largest US biotech exit in 2024 was Vertex Pharmaceuticals $4.9 Immunology deals stood out, including Vertex Pharmaceuticals $4.9 from 2023. [1]

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64

Focus Investment Banking

FEBRUARY 11, 2025

Traditional terminal exit routes for private equity-backed companies are to larger strategic acquirers (often public companies) and IPOs, where a private company becomes publicly traded. McKesson is primarily a distributor, meaning that it sells pharmaceuticals, medical supplies, and other medical devices and services to healthcare providers.

Private Equity 52

Private Equity Healthcare Equities Medical 52

Cooley M&A

FEBRUARY 15, 2017

Dealmakers appear much more optimistic in the first quarter of 2017 than at this same time last year, in part because of greater optimism about the IPO market and the potential for favorable corporate tax and other regulatory changes. We expect this trend to continue, with mid-market and smaller deals driving the deal count in 2017.

M&A 40

M&A IPO Pharmaceutical Valuation 40

Growth Business

APRIL 10, 2025

The life sciences sector is popular, with 53 pharmaceutical companies created to date. Theyve made an impressive four exits, made up of two acquisitions and two IPOs. billion in 2024, an impressive 34 per cent increase on 2023. Whats more, 24 per cent of Oxfords spinout founders are female, which is well above the national average.

Equities 65

Equities Engineering Investors Funds 65